

DRUG PRIOR AUTHORIZATION COMMITTEE

June 16, 2011
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Acting Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update	Rhonda Driver/ Andrew Haslag
11:30 - 11:35	DUR Update	Rhonda Driver

Old Business

11:35 - 11:45	a. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
---------------	--	---------------

New Business

11:45 – 12:15	New Drug/Product Reviews	
	a. Proposed Actions (See website and Attached Summary)	
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
	• Discussion	
	• Public Hearing	
	• Decision	
	b. Clinical Edits	
	i. Non-Oral Contraceptives	
	• Discussion	
	• Public Hearing	
	• Decision	

12:15-1:30	<i>Proposed New Program Actions of Existing Products</i>	
------------	--	--

- | | |
|---|--|
| a. Drug List (PDL) | |
| i. Amylin Analogs | |
| • Discussion | |
| • Public Hearing | |
| • Decision | |
| ii. Beta Blockers | |
| • Discussion | |
| • Public Hearing | |
| • Decision | |
| iii. Calcium Channel Blockers/Dihydropyridines | |
| • Discussion | |
| • Public Hearing | |
| • Decision | |
| iv. Calcium Channel Blockers/ Non-Dihydropyridines | |
| • Discussion | |
| • Public Hearing | |
| • Decision | |
| v. Calcium Channel Blocker/ARB Combinations | |
| • Discussion | |
| • Public Hearing | |
| • Decision | |
| vi. Cox II Inhibitors | |
| • Discussion | |
| • Public Hearing | |
| • Decision | |

- vii. **DPP-IV Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- viii. **GLP -1 Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
- ix. **Hepatitis C Agents**
 - Discussion
 - Public Hearing
 - Decision
- x. **Onychomycosis Antifungals**
 - Discussion
 - Public Hearing
 - Decision
- xi. **Proton Pump Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- xii. **Ribavirins**
 - Discussion
 - Public Hearing
 - Decision
- xiii. **Topical Androgen Agents**
 - Discussion
 - Public Hearing
 - Decision
- xlv. **Topical Immunomodulators**
 - Discussion
 - Public Hearing
 - Decision

b. Preferred Drug List

- i. Process discussion or questions
- ii. Therapeutic classes-to be *announced at meeting*

1:30 **LUNCH**

1:45-2:00 **Program Utilization Information**

2:00-2:30 **Other Business**

- i. *Top 25" Drugs by Cost*
- ii. *Clinical Edit Summary Report*
- iii. *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

2:30-2:35	Minutes Review	Discussion/Approval
2:35-3:00	Case Reviews	Rhonda Driver/ Jenna Twehus

NEXT MEETING: September 15, 2011 – 205 Jefferson Street, 10th Floor